The association between the PTPN22 C1858T polymorphism and systemic sclerosis: A meta-analysis

Molecular Biology Reports

Volumn 39, Issue 3, 2012, Pages 3103-3108

  Lee, Young Ho ^a   Choi, Sung Jae ^a   Ji, Jong Dae ^a   Song, Gwan Gyu ^a  

^a College of Medicine   (South Korea)

Author keywords

Meta analysis; Polymorphism; Protein tyrosine phosphatase nonreceptor 22; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; CYTOSINE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; THYMINE; TOPOISOMERASE ANTIBODY; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; CONFIDENCE INTERVAL; ETHNIC DIFFERENCE; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HISPANIC; HUMAN; PREVALENCE; PTPN22 GENE; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS;

AFRICAN AMERICANS; ANTIBODIES, ANTINUCLEAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, STATISTICAL; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; PUBLICATION BIAS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84863843845     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1074-x     Document Type: Article

References (16)

1. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989-2003
2. Arnett FC (2006) Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 18(6):579-581
3. Cloutier JF, Veillette A (1999) Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 189(1):111-121
4. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M et al (2004) A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 36(4):337-338
5. Diaz-Gallo LM, Gourh P, Broen J, Simeon C, Fonollosa V, Ortego-Centeno N et al (2011) Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 70(3):454-462
6. Dieude P, Guedj M, Wipff J, Avouac J, Hachulla E, Diot E et al (2008) The PTPN22 620 W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians, a meta-analysis. Arthritis Rheum 58(7):2183-2188
7. Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach Met al (2006) Association of the PTPN22 R620 Wpolymorphism with anti-topoisomerase I-and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 54(12):3945-3953
8. Balada E, Simeon-Aznar CP, Serrano-Acedo S, Martinez-Lostao L, Selva-O'Callaghan A, Fonollosa-Pla V et al (2006) Lack of association of the PTPN22 gene polymorphism R620 W with systemic sclerosis. Clin Exp Rheumatol 24(3):321-324
9. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ. 315(7109):629-634
10. Davey Smith G, Egger M (1997) Meta-analyses of randomised controlled trials. Lancet 350(9085):1182
11. Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315(7121):1533-1537
12. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188
13. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558
14. Wipff J, Allanore Y, Kahan A, Meyer O, Mouthon L, Guillevin L et al (2006) Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)*620 W allele, systemic sclerosis in the French Caucasian population. Ann Rheum Dis 65(9):1230-1232
15. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK et al (2007) The PTPN22 C1858T functional polymorphism, autoimmune diseases-a meta-analysis. Rheumatol (Oxford) 46(1):49-56
16. Orru V, Tsai SJ, Rueda B, Fiorillo E, Stanford SM, Dasgupta J et al (2009) A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 18(3):569-579